Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors, the benefits of adding ovarian function suppression (OFS) to endocrine therapy have been debated. Consequently, for many years...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yen-Shen, Wong, Andrea, Kim, Hee-Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477635/
https://www.ncbi.nlm.nih.gov/pubmed/34595110
http://dx.doi.org/10.3389/fonc.2021.700722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477635/
https://www.ncbi.nlm.nih.gov/pubmed/34595110
http://dx.doi.org/10.3389/fonc.2021.700722

Ejemplares similares